Brief: Tetra Bio-Pharma Receives FDA Orphan Drug Designation For Hepatocellular Carcinoma
04/12/2019 13:21
Dec 4 (Reuters) - Tetra Bio Pharma Inc TBP.V :
* TETRA BIO-PHARMA RECEIVES FDA ORPHAN DRUG DESIGNATION FOR
HEPATOCELLULAR CARCINOMA
* TETRA BIO PHARMA - TO LAUNCH PHASE 2 TRIAL FOR TREATMENT
OF
HEPATOCELLULAR CARCINOMA IN Q1 2020
Source text for Eikon: ID:nGNX4dLJVX
Further company coverage: TBP.V
(Reporting by Dominic Roshan K L)
((Dominic.RoshanKL@thomsonreuters.com;))
Recent news on Tetra Bio Pharma
See all newsBrief: Tetra Bio Receives A Second Clarifax From Health Canada Regarding Reduvo Risk Management Plan
Brief: Tetra Bio-Pharma Announces Results Of Artificial Intelligence Study Of ARDS-003 Combined With Favipiravir
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra And Prepaire Jointly Apply To Barda For Funding